STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Comments
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	'Cohort study' in title and abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	See abstract
Introduction			
Background / rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 6
Methods			
Study design	4	Present key elements of study design early in the paper	Page 6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pages 6-7
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Pages 6-7 (participant selection), page 9 (follow-up)
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pages 7-8
Data sources / measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pages 7-8
Bias	9	Describe any efforts to address potential sources of bias	Pages 9-10 (statistical analysis), Supplementary Methods
Study size	10	Explain how the study size was arrived at	All available patients were used
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 7 (rationale for categories), pages 9-10 (statistical analysis), Supplementary Methods
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Pages 9-10, Supplementary Methods
		(*b*) Describe any methods used to examine subgroups and interactions	Pages 9-10
		(*c*) Explain how missing data were addressed	Page 10. Supplementary Methods
		(*d*) If applicable, explain how loss to follow-up was addressed	Page 9, Supplementary Methods
		(*e*) Describe any sensitivity analyses	Page 10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	Figure 1
		(b) Give reasons for non-participation at each stage	Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1 caption (page 27)
		(c) Summarize follow-up time (eg, average and total amount)	Results, page 10
Outcome data	15*	Report numbers of outcome events or summary measures over time	Results, page 10
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Figures 2 and 3
		(*b*) Report category boundaries when continuous variables were categorized	Table 1
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary Figures 2-6, 8-11
Discussion			
Key results	18	Summarize key results with reference to study objectives	Page 12, first paragraph of Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 15-16, Conclusions
Generalizability	21	Discuss the generalizability (external validity) of the study results	Pages 15-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding information and competing interests declaration provided.

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.